

Attorney Docket No. P28933

Application No. 10/560,230

Tfw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Chikara MURAKATA et al. Confirmation No.: 4996

Serial No : 10/560,230 Group Art Unit: 1626
(National Stage of PCT/JP2004/008375)

I.A. Filed : June 9, 2004 Examiner: S. YOUNG

For : THIADIAZOLINE DERIVATIVE

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, and supplemental to the Information Disclosure Statements previously filed on December 1, 2006; April 10, 2007; May 10, 2007; and August 5, 2008, Applicants hereby direct the Examiner's attention to the following documents, which are cited in the Supplementary Partial European Search Report for European Application No. EP 04 72 8012, of which the counterpart U.S. application No. 10/553,222 is commonly assigned and copending with the above-referenced application. The European Examiner cites:

- (1) WO 2004111023 A1, Applicants note that this document was cited and listed in the Third Supplemental Information Disclosure Statement filed August 5, 2008;

- (2) EP 1 632 484 A1, March 8, 2006; Applicants note that this document is the published counterpart application of the present U.S. Application; and
- (3) EP 1 671 957 A1, June 21, 2006; Applicants note that this document is a family member of US Application No. 10/575,093 (published as US 2007/0112044 A1, May 17, 2007), which was cited and listed in the Supplemental Information Disclosure Statement filed April 10, 2007.

Copies of documents (2) and (3), and the Supplementary Partial European Search Report for European Application No. EP 04 72 8012 are enclosed together with a completed copy of the Form PTO-1449 listing these documents. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the Form PTO-1449 with the next communication.


Further to 37 C.F.R. §1.98 (a)(2)(ii) and the U.S. Patent and Trademark Office's decision to waive the requirement under 37 C.F.R. §1.98 (a)(2)(iii) if the U.S. patent application was filed after June 30, 2003, copies of the U.S. patent applications cited above are not enclosed herewith. However, if any copy is needed, the Examiner is respectfully requested to contact the undersigned.

Applicants note that an Office Action on the merits has not yet issued in the instant application, and thus, no fee is necessary to ensure consideration of this statement. However, if an Office Action has issued and is crossing in the mail with this statement, the Patent and

Trademark Office is hereby authorized to charge Deposit Account No. 19-0089 any fee necessary to ensure consideration of the submitted materials.

If there are any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Chikara MURAKATA, et al.


Bruce H. Bernstein
Reg. No. 29,027


November 17, 2008
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191